Yüklüyor......
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis. The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemi...
Kaydedildi:
| Yayımlandı: | J Gastrointest Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AME Publishing Company
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5401857/ https://ncbi.nlm.nih.gov/pubmed/28480065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.09.07 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|